Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MAIA | S-3 | bearish | 5/10 | MAIA Biotechnology filed an S-3 registration statement to register 751,879 shares of common stock for resale by PoC Capi | Sep 25, 2026 |
| VNRX | 8-K | bearish | 7/10 | VolitionRx issued 2,157,340 shares to Lind Global Asset Management XII LLC via two debt conversions totaling $525,000, f | Sep 25, 2026 |
| PULM | DEFM14A | bearish | 6/10 | Pulmatrix is asking stockholders to vote on a reverse merger with Eos SENOLYTIX, a preclinical biotech developing mitoch | Sep 25, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $2.45M in open-market shares over a one-week window. Rothblatt' | Sep 25, 2026 |
| COAG | 3 | neutral | 2/10 | Keli Walbert filed a Form 3 initial statement of beneficial ownership with Hemab Therapeutics Holdings, Inc. (COAG), ind | Sep 25, 2026 |
| BLRX | F-1 | neutral | 4/10 | BioLineRx filed an F-1 registration statement to register 2,023,382 ADSs for resale by Armistice Capital, the sole selli | Sep 25, 2026 |
| NRSN | 6-K | bearish | 7/10 | NeuroSense Therapeutics reported H1 2026 financial results showing a net loss of $3.6 million (improved from $4.7 millio | Sep 25, 2026 |
| NGEN | 6-K | bearish | 7/10 | NervGen Pharma announced it will restate financial statements for FY2024, FY2025, and Q2 2026 due to non-cash valuation | Sep 25, 2026 |
| TPST | S-3 | bearish | 6/10 | Tempest Therapeutics filed an S-3 registration statement to register up to 9,534,164 shares of common stock for resale b | Sep 25, 2026 |
| NGEN | PRESS-RELEASE | neutral | 4/10 | NervGen Pharma announced a non-cash restatement of its 2025 annual and Q2 2026 interim financial statements, revising th | Sep 25, 2026 |
| DFTX | 144 | neutral | 2/10 | Mark Sullivan, an officer of Definium Therapeutics, filed a Form 144 on September 25, 2026, indicating intent to sell 14 | Sep 25, 2026 |
| ENLV | 6-K | neutral | 5/10 | Enlivex reported H1 2026 net income of $1.95B driven entirely by non-cash, unrealized gains on its RAIN digital asset ho | Sep 25, 2026 |
| SLXN | 8-K | bearish | 7/10 | Silexion Therapeutics received a Nasdaq Staff letter on September 25, 2026, notifying the company that its ordinary shar | Sep 25, 2026 |
| DFTX | 144 | neutral | 2/10 | Brandi Roberts, an officer of Definium Therapeutics, filed a Form 144 on September 25, 2026, indicating intent to sell 3 | Sep 25, 2026 |
| ADAG | 6-K | neutral | 2/10 | Adagene Inc. filed a 6-K reporting the resignation of Ms. Chunfang (Vicky) Gu as Executive Director of Finance, effectiv | Sep 25, 2026 |
| DFTX | 144 | neutral | 3/10 | Director Matthew T. Wiley filed a Form 144 notice of intent to sell 3,097 shares of Definium Therapeutics (DFTX) with an | Sep 25, 2026 |
| TCRX | SC 13G | neutral | 3/10 | Readout Capital, LP disclosed a new 5.4% passive stake in TScan Therapeutics via a Schedule 13G filed September 25, 2026 | Sep 25, 2026 |
| NXTC | 425 | neutral | 5/10 | NextCure filed a Section 205 petition in Delaware Chancery Court seeking validation of its July 2025 reverse stock split | Sep 25, 2026 |
| NXTC | 8-K | neutral | 5/10 | NextCure filed a Section 205 petition in the Delaware Court of Chancery seeking judicial validation of its July 2025 rev | Sep 25, 2026 |
| GTBP | 8-K | neutral | 3/10 | GT Biopharma regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common stock closed above $ | Sep 25, 2026 |
| STOK | 8-K | neutral | 2/10 | Stoke Therapeutics disclosed the resignation of board member Dr. Edward M. Kaye and the immediate appointment of Alexand | Sep 25, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three TWST insiders, including CEO Emily Leproust, sold a total of ~$273K in open-market sales over a 7-day window. The | Sep 25, 2026 |
| TBPH | SC 13D/A | neutral | 4/10 | Weiss Asset Management LP filed a Schedule 13D/A reporting that its stake in Theravance Biopharma was reduced to 0% as o | Sep 25, 2026 |
| BMRA | S-3 | bearish | 6/10 | Biomerica filed a $250M universal shelf registration statement (S-3) on September 24, 2026, registering common stock, pr | Sep 25, 2026 |
| KPTI | SC 13G/A | neutral | 3/10 | Acorn Bioventures L.P. and related entities filed an amended Schedule 13G disclosing an aggregate beneficial ownership o | Sep 25, 2026 |
| PHVS | CLUSTER | bearish | 6/10 | A significant insider selling cluster at Pharvaris N.V. (PHVS) totaling $7.46M in open-market sales over a one-week peri | Sep 25, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech announced new preclinical data at the AACR Pancreatic Cancer Conference showing that the antitumor act | Sep 25, 2026 |
| SLS | PRESS-RELEASE | neutral | 3/10 | SELLAS Life Sciences presented preclinical data at AACR showing its CDK9 inhibitor SLS009 induced substantially greater | Sep 25, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) to treat childr | Sep 25, 2026 |
| KPTI | SC 13G/A | neutral | 3/10 | Acorn Bioventures, L.P. and related entities filed an amended Schedule 13G disclosing a combined beneficial ownership of | Sep 25, 2026 |